Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EP-088_MM09 in Mite-allergic Rhinitis/Rhinoconjunctivitis
NCT07904195Phase 3Recruiting
- Sponsor
- Inmunotek
- Start
- Apr 2026
- Primary completion
- Jul 2029
- Countries
- 2
01
Overview
A Phase 3 trial of EP-088_MM09 in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC), allergic asthma, sponsored by Inmunotek. Started Apr 2026; status: recruiting.
02
Drugs
EP-088_MM09
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)allergic asthma
Beyond the preview
Go deeper on NCT07904195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07904195.